Initiating Therapy When to Start, What to Use

Hirsch, Martin S.
May 2008
Journal of Infectious Diseases;5/15/2008 Supplement 3, pS252
Academic Journal
Decisions regarding whether to start combination antiretroviral therapy (cART) during primary infection and when to initiate treatment during chronic infection continue to evolve. Although current data suggest that there may be a benefit to therapy during primary infection, results are inconclusive. Once begun, treatment probably should be continued indefinitely, since its potential advantages disappear over time if treatment is stopped. Recent studies suggest that cART maybe useful at higher CD4 cell count thresholds than are currently recommended in several guidelines. Several regimens are acceptable as initial therapy, with tenofovir/emtricitabine/efavirenz favored by many because of potency and ease of administration. Other favored regimens include combinations of 2 nucleoside (or nucleotide) reverse-transcriptase inhibitors and a ritonavir-boosted protease inhibitor. Some new antiretroviral drugs under study, particularly integrase inhibitors, may prove useful in treatment-naive patients.


Related Articles

  • Telbivudine - a Promising New Antiviral Agent in Patients with Chronic Hepatitis B. Ciobanu, Andrea // Maedica - a Journal of Clinical Medicine;2007, Vol. 2 Issue 4, p346 

    The article reports on the study that evaluates the efficacy of telbivudine antiviral agents to treat chronic hepatitis B. It has found out that telbivudine was significantly superior to lamivudine concerning all the primary and secondary end points among HBeAG-positive patients and has...

  • Cost-Effectiveness Analysis of Antiviral Therapies for Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients in China. Zhang, Chi; Ke, Weixia; Gao, Yanhui; Zhou, Shudong; Liu, Li; Ye, Xiaohua; Yao, Zhenjiang; Yang, Yi // Clinical Drug Investigation;Mar2015, Vol. 35 Issue 3, p197 

    Background and Objective: Several antiviral therapies are now available for patients with chronic hepatitis B (CHB), but the most cost-effective strategy for Chinese patients is unclear. The aim of this study was to estimate the long-term cost effectiveness of the antiviral treatments...

  • Targeting Nucleotide Dimers Containing Antiviral Nucleosides. Rossi, L.; Serafini, S.; Franchetti, P.; Cappellacci, L.; Fraternale, A.; Casabianca, A.; Brandi, G.; PierigĂ©, F.; Perno, C-F; Balestra, E.; Benatti, U.; Millo, E.; Grifantini, M.; Magnani, M. // Current Medicinal Chemistry - Anti-Infective Agents;Jan2005, Vol. 4 Issue 1, p37 

    Among the antiviral agents developed for the treatment of human viral infections, nucleoside analogs represent the largest group. However, much remains to do to improve their pharmacokinetic properties, to increase their efficacy, to reduce the selection of drug-resistent strains and to reduce...

  • Scientists Disagree to Disagree on Influenza A Channel Structure. Breindl, Anette // BioWorld Today;1/31/2008, Vol. 19 Issue 21, p1 

    The article reports on two research groups, which presented in the January 31, 2008 issue of "Nature," what each believes to be the binding mechanism of the anti-influenza drug amantadine to its target, the M2 channel. It was noted that the two groups agree on the basic structure of the channel,...

  • Triple Nucleoside Reverse Transcriptase Inhibitor Therapy in Children. Handforth, Jennifer; Sharland, Mike // Pediatric Drugs;2004, Vol. 6 Issue 3, p147 

    Much of the success attributed to HIV therapy in the last few years has resulted from improved ways of using existing drugs in combination therapy regimens. The availablity of new, more potent drugs such as protease inhibitors and more accurate viral load tests to aid decisions to start or...

  • Improving adherence to antiretroviral therapy. Nischal, K. C.; Khopkar, Uday; Saple, D. G. // Indian Journal of Dermatology, Venereology & Leprology;Sep/Oct2005, Vol. 71 Issue 5, p316 

    Antiretroviral therapy (ART) has transformed HIV infection into a treatable, chronic condition. However, the need to continue treatment for decades rather than years, calls for a long-term perspective of ART. Adherence to the regimen is essential for successful treatment and sustained viral...

  • Can Responses to Antiretroviral Therapy Be Improved by Therapeutic Drug Monitoring? Haas, David W. // Clinical Infectious Diseases;4/15/2006, Vol. 42 Issue 8, p1197 

    The article focuses on several studies which investigate whether therapeutic drug monitoring can help improve the outcomes of antiretroviral therapy. In some studies, therapeutic drug monitoring was associated with an increased likelihood of virological success. While other trials have failed to...

  • Ribavirin Protects Syrian Hamsters against Lethal Hantavirus Pulmonary Syndrome - After Intranasal Exposure to Andes Virus. Ogg, Monica; Jonsson, Colleen B.; Camp, Jeremy V.; Hooper, Jay W. // Viruses (1999-4915);Nov2013, Vol. 5 Issue 11, p2704 

    Andes virus, ANDV, harbored by wild rodents, causes the highly lethal hantavirus pulmonary syndrome (HPS) upon transmission to humans resulting in death in 30% to 50% of the cases. As there is no treatment for this disease, we systematically tested the efficacy of ribavirin in vitro and in an...

  • A Prospective Assessment of Valganciclovir for the Treatment of Cytomegalovirus Infection and Disease in Transplant Recipients. Humar, Atul; Siegal, Deborah; Moussa, George; Kumar, Deepali // Journal of Infectious Diseases;10/1/2005, Vol. 192 Issue 7, p1154 

    We assessed valganciclovir for the treatment of cytomegalovirus (CMV) in organ-transplant recipients. Virologic and clinical outcomes were compared with those in matched historical control individuals. Thirty-two patients (23 with symptomatic disease) received valganciclovir, and 32 patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics